The prize was awarded jointly to Katalin Karikó and Drew Weissman for their groundbreaking discovery regarding the modification of the bases in mRNA. On Oct. 2, 2023, The Nobel Prize in Physiology or Medicine was awarded jointly to Katalin Karikó and Drew Weissman for their work on nucleoside base modifications
The BioIndustry Association reports that with a strong foundation in research and development in mRNA, the United Kingdom will be a major player in this rapidly growing industry. On Oct 4, 2023, the BioIndustry Association (BIA) released a new report detailing how the United Kingdom is positioned to become a
The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions. On Oct. 2, 2023, Advent International (Advent), a global private equity investor, and Warburg Pincus, a global growth investor, announced that they have completed their previously announced acquisition of Baxter International’s BioPharma Solutions
Under the partnership, Sartorius will leverage SPARTA Biodiscovery’s technology to accelerate the development of nanoparticles used for drug delivery. On Sept. 28, 2023, Sartorius and UK-based startup SPARTA Biodiscovery (SPARTA) announced that they have entered into a partnership for SPARTA’s analysis platform. The platform helps speed the development,
The contract is part of the US Department of Health and Human Services’ ‘Project NextGen’ initiative, aimed at pushing forward new and stronger COVID-19 vaccines and therapies. On Sept. 27, 2023, Gritstone Bio, a clinical-stage biotechnology company, announced it has been awarded a contract by the Biomedical Advanced Research and
The European Commission has approved Tyruko (natalizumab), a biosimilar developed by Polpharma Biologics for treating multiple sclerosis. Polpharma Biologics, a biotech company headquartered in Poland, announced on Sept. 26, 2023, that the European Commission (EC) approved Tyruko (natalizumab), a biosimilar for treating relapsing forms of multiple sclerosis (MS). The biosimilar
With the two new GMP-grade mRNA manufacturing sites in Germany, MilliporeSigma can now offer fully integrated mRNA services. MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced on Sept. 26, 2023 that it has opened two new good manufacturing practice (GMP)-grade messenger RNA (mRNA)
The tools, originally utilized during the COVID-19 pandemic, are now intended to work alongside FDA’s standard procedures. On Sept. 21, 2023, the FDA released a new guidance on how the agency plans to utilize alternative tools to remotely evaluate drug manufacturing facilities identified in a marketing application. The application
Under a new pact, Genentech and PeptiDream will collaborate to discover and develop novel peptide-radioisotope drug conjugates. PeptiDream, a public Kanagawa, Japan-based biopharmaceutical company, has entered into a new multi-target collaboration and license agreement with Genentech, a member of the Roche Group, in which the companies will work to discover
The companies plan on targeting the production of abundant, low-cost messenger RNA from C1-cells. Dyadic International, a biotechnology company that builds microbial platforms, announced on Sept. 26, 2023 a collaboration with bYoRNA SAS, a French biotechnology company developing scalable mRNA bioproduction platforms. The development and commercialization agreement the companies have
BenevolentAI will leverage its suite of AI chemistry design tools in combination with its fully equipped wet lab facility in Cambridge, UK, to deliver small molecule drug development candidates into the Merck pipeline, according to the press release. BenevolentAI, a company that is a part of the development of advanced